title: [Retrospective analysis of tegafur/uracil (UFT) plus oral leucovorin (LV) regimen in patients with advanced colorectal cancer].
abstract: The clinical efficacy and safety of tegafur/uracil (UFT) plus oral Leucovorin (LV) regimen for advanced or metastatic colorectal cancer were studied retrospectively. From September 2003 to March 2005, 82 patients were treated with UFT (300 mg/m(2)/day)/LV (75 mg/day) at our institute. The objective overall response rate was 14. 8% (95% confidence interval, 5.3 to 24.3%) in 54 evaluable patients. The response rate was 33.3% for previously untreated patients and 5.5% for previously treated patients, respectively. Grade 3 or more severe adverse reactions such as diarrhea or liver function abnormalities were only 7.3%. In 28 previously untreated patients,the median survival was 25.8 months with 1-and 2-year survival rates of 88.0% and 60.5%, respectively. This retrospective study demonstrated the reproducible activity and safety of UFT/LV for advanced or metastatic colorectal cancer in clinical practice.
authors.affiliation: Dept. of Diagnostic and Interventional Radiology, Aichi Cancer Center, National Cancer Center Hospital.
authors.forename: Yozo
authors.initials: Y
authors.lastname: Sato
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Inaba
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Yamaura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shimamoto
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Nishiofuku
authors.forename: Takashi
authors.initials: T
authors.lastname: Oyama
authors.forename: Yukihide
authors.initials: Y
authors.lastname: Kanemitsu
authors.forename: Akira
authors.initials: A
authors.lastname: Sawaki
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Arai
authors.forename: Kei
authors.initials: K
authors.lastname: Muro
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage; D014840:Vomiting, Anticipatory / Q000139:chemically induced
chemical_list: D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D014498:Uracil; D002955:Leucovorin